vs
碧迪（BDX）与史丹利百得（SWK）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是史丹利百得的1.4倍（$5.3B vs $3.8B），碧迪净利率更高（7.3% vs 1.4%，领先5.9%），史丹利百得同比增速更快（0.1% vs -0.4%），碧迪自由现金流更多（$549.0M vs $155.3M），过去两年碧迪的营收复合增速更高（2.0% vs 0.3%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
史丹利百得是美国知名的工业工具、家用五金产品制造商，同时提供安防类产品，前身为史丹利工具有限公司，由史丹利与百得于2010年3月12日合并而来，总部位于康涅狄格州大哈特福德地区的新不列颠市。
BDX vs SWK — 直观对比
营收规模更大
BDX
是对方的1.4倍
$3.8B
营收增速更快
SWK
高出0.5%
-0.4%
净利率更高
BDX
高出5.9%
1.4%
自由现金流更多
BDX
多$393.7M
$155.3M
两年增速更快
BDX
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.8B |
| 净利润 | $382.0M | $51.4M |
| 毛利率 | 45.9% | 31.4% |
| 营业利润率 | 10.5% | — |
| 净利率 | 7.3% | 1.4% |
| 营收同比 | -0.4% | 0.1% |
| 净利润同比 | 24.0% | -43.6% |
| 每股收益（稀释后） | $1.34 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXSWK
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.9B | $3.8B | ||
| Q2 25 | $5.5B | $3.9B | ||
| Q1 25 | $5.3B | $3.7B | ||
| Q4 24 | $5.2B | $3.7B | ||
| Q3 24 | $5.4B | $3.8B | ||
| Q2 24 | $5.0B | $4.0B | ||
| Q1 24 | $5.0B | $3.9B |
净利润BDXSWK
| Q4 25 | $382.0M | — | ||
| Q3 25 | $493.0M | $51.4M | ||
| Q2 25 | $574.0M | $101.9M | ||
| Q1 25 | $308.0M | $90.4M | ||
| Q4 24 | $303.0M | $194.9M | ||
| Q3 24 | $400.0M | $91.1M | ||
| Q2 24 | $487.0M | $-11.2M | ||
| Q1 24 | $537.0M | $19.5M |
毛利率BDXSWK
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | 31.4% | ||
| Q2 25 | 47.8% | 27.0% | ||
| Q1 25 | 42.8% | 29.9% | ||
| Q4 24 | 43.2% | 30.8% | ||
| Q3 24 | 45.7% | 29.9% | ||
| Q2 24 | 46.2% | 28.4% | ||
| Q1 24 | 45.7% | 28.6% |
营业利润率BDXSWK
| Q4 25 | 10.5% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | 8.8% | 3.4% | ||
| Q3 24 | 11.4% | 10.6% | ||
| Q2 24 | 12.1% | 9.5% | ||
| Q1 24 | 14.5% | 8.3% |
净利率BDXSWK
| Q4 25 | 7.3% | — | ||
| Q3 25 | 8.4% | 1.4% | ||
| Q2 25 | 10.4% | 2.6% | ||
| Q1 25 | 5.8% | 2.4% | ||
| Q4 24 | 5.9% | 5.2% | ||
| Q3 24 | 7.4% | 2.4% | ||
| Q2 24 | 9.8% | -0.3% | ||
| Q1 24 | 10.6% | 0.5% |
每股收益（稀释后）BDXSWK
| Q4 25 | $1.34 | — | ||
| Q3 25 | $1.71 | $0.34 | ||
| Q2 25 | $2.00 | $0.67 | ||
| Q1 25 | $1.07 | $0.60 | ||
| Q4 24 | $1.04 | $1.29 | ||
| Q3 24 | $1.37 | $0.60 | ||
| Q2 24 | $1.68 | $-0.07 | ||
| Q1 24 | $1.85 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $268.3M |
| 总债务越低越好 | — | $5.3B |
| 股东权益账面价值 | $25.3B | $9.0B |
| 总资产 | $54.8B | $21.8B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资BDXSWK
| Q4 25 | $740.0M | — | ||
| Q3 25 | $641.0M | $268.3M | ||
| Q2 25 | $735.0M | $311.8M | ||
| Q1 25 | $667.0M | $344.8M | ||
| Q4 24 | $711.0M | $290.5M | ||
| Q3 24 | $1.7B | $298.7M | ||
| Q2 24 | $4.5B | $318.5M | ||
| Q1 24 | $2.3B | $476.6M |
总债务BDXSWK
| Q4 25 | — | — | ||
| Q3 25 | — | $5.3B | ||
| Q2 25 | — | $5.6B | ||
| Q1 25 | — | $5.6B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $6.1B | ||
| Q1 24 | — | $6.1B |
股东权益BDXSWK
| Q4 25 | $25.3B | — | ||
| Q3 25 | $25.4B | $9.0B | ||
| Q2 25 | $25.5B | $9.1B | ||
| Q1 25 | $25.2B | $8.8B | ||
| Q4 24 | $25.2B | $8.7B | ||
| Q3 24 | $25.9B | $8.9B | ||
| Q2 24 | $25.9B | $8.7B | ||
| Q1 24 | $25.6B | $8.9B |
总资产BDXSWK
| Q4 25 | $54.8B | — | ||
| Q3 25 | $55.3B | $21.8B | ||
| Q2 25 | $54.9B | $22.5B | ||
| Q1 25 | $54.5B | $22.5B | ||
| Q4 24 | $54.7B | $21.8B | ||
| Q3 24 | $57.3B | $22.5B | ||
| Q2 24 | $55.6B | $22.5B | ||
| Q1 24 | $54.2B | $23.9B |
负债/权益比BDXSWK
| Q4 25 | — | — | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $221.2M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $155.3M |
| 自由现金流率自由现金流/营收 | 10.5% | 4.1% |
| 资本支出强度资本支出/营收 | 2.1% | 1.8% |
| 现金转化率经营现金流/净利润 | 1.72× | 4.30× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $369.6M |
8季度趋势，按日历期对齐
经营现金流BDXSWK
| Q4 25 | $657.0M | — | ||
| Q3 25 | $1.4B | $221.2M | ||
| Q2 25 | $1.2B | $214.3M | ||
| Q1 25 | $164.0M | $-420.0M | ||
| Q4 24 | $693.0M | $679.1M | ||
| Q3 24 | $1.2B | $285.8M | ||
| Q2 24 | $1.3B | $573.0M | ||
| Q1 24 | $514.0M | $-431.0M |
自由现金流BDXSWK
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | $155.3M | ||
| Q2 25 | $1.0B | $134.7M | ||
| Q1 25 | $35.0M | $-485.0M | ||
| Q4 24 | $588.0M | $564.6M | ||
| Q3 24 | $882.0M | $199.3M | ||
| Q2 24 | $1.1B | $485.8M | ||
| Q1 24 | $380.0M | $-496.7M |
自由现金流率BDXSWK
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | 4.1% | ||
| Q2 25 | 19.0% | 3.4% | ||
| Q1 25 | 0.7% | -13.0% | ||
| Q4 24 | 11.4% | 15.2% | ||
| Q3 24 | 16.2% | 5.3% | ||
| Q2 24 | 22.4% | 12.1% | ||
| Q1 24 | 7.5% | -12.8% |
资本支出强度BDXSWK
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | 1.8% | ||
| Q2 25 | 3.2% | 2.0% | ||
| Q1 25 | 2.4% | 1.7% | ||
| Q4 24 | 2.0% | 3.1% | ||
| Q3 24 | 5.4% | 2.3% | ||
| Q2 24 | 3.6% | 2.2% | ||
| Q1 24 | 2.7% | 1.7% |
现金转化率BDXSWK
| Q4 25 | 1.72× | — | ||
| Q3 25 | 2.75× | 4.30× | ||
| Q2 25 | 2.12× | 2.10× | ||
| Q1 25 | 0.53× | -4.65× | ||
| Q4 24 | 2.29× | 3.48× | ||
| Q3 24 | 2.94× | 3.14× | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | -22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
SWK
| Tools And Outdoor Segment | $3.3B | 87% |
| Engineered Fastening Segment | $500.5M | 13% |
